Business
Helix BioPharma to Present at the BioFinance 2009 Conference
AURORA, Ontario, April 24 /CNW/ -- Helix BioPharma Corp. (TSX, FSE: "HBP") today announced that J...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\nAURORA, Ontario, April 24 /CNW/ -- Helix BioPharma Corp. (TSX, FSE:\n"HBP") today announced that John Docherty, president and chief operating\nofficer, will present at the BioFinance 2009 Investor Conference at 3:00 p.m.\nEDT on Wednesday, April 29, at The Toronto Marriott in Toronto. Mr. Docherty\nwill provide an overview of the company's leading technology platforms, DOS47\nand Biphasix(TM), and its current product development programs, L-DOS47 and\nTopical Interferon Alpha-2b. The slide show portion of the presentation will\nbe posted on the Company's website, www.helixbiopharma.com, on April 29, 2009.\n\n\n\nAbout Helix BioPharma Corp.\n\n\n\nHelix BioPharma Corp. is a biopharmaceutical company specializing in the\nfield of cancer therapy. The Company is actively developing innovative\nproducts for the prevention and treatment of cancer based on its proprietary\ntechnologies. Helix's product development initiatives include its Topical\nInterferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed\non the TSX under the symbol "HBP".\n\n\n\nFor further information contact:\n\n\nInvestor & Media Relations\nIan Stone Robert Flamm, Ph.D.\nRusso Partners LLC Russo Partners LLC\nTel: (619) 814-3510 Tel: (212) 845-4226\nFax: (619) 955-5318 Email:\nEmail: [email protected]\n [email protected] www.russopartnersllc.com\n\n\n\nThis News Release contains certain forward-looking statements regarding\nthe Company's planned presentation at the BioFinance 2009 Investor Conference\nand the Company's research and development initiatives, which statements can\nbe identified by the use of forward-looking terminology such as "will",\n"developing", "April 29", or comparable terminology referring to future events\nor results. Forward looking statements are statements about the future and are\ninherently uncertain, and Helix's actual results could differ materially from\nthose anticipated in these forward-looking statements as a result of numerous\nfactors, including without limitation, the risk that the BioFinance\npresentation and the posting of the slide show portion of the presentation are\nsubject to change or cancellation without notice; uncertainty whether L-DOS47\nor Topical Interferon Alpha-2b will be successfully developed as a drug o...